Literature DB >> 1315587

Herpesviruses--immune escape artists?

T A Banks1, B T Rouse.   

Abstract

Viral persistence depends on the successful avoidance of the host's immunologic surveillance system. This review, which focuses specifically on the herpesviruses, delineates several possible strategies for evading or delaying the immune response. One strategy common to all herpesviruses is the establishment of latency, a state in which the virus may be partially or even completely hidden from the immune system. Other proposed mechanisms of immune evasion include interaction of the virus with components of the humoral immune system, virus-induced modulation of cell-surface recognition structures, and virally mediated interference in antigen processing. Additional strategies include molecular mimicry and the ability of one particular herpesvirus to encode an immunosuppressive cytokine. Although a detailed understanding of the molecular mechanisms of herpesvirus-mediated immune evasion is currently lacking, future studies should identify those critical interactions between host and virus that may prove amenable to therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315587     DOI: 10.1093/clinids/14.4.933

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

1.  A rhesus macaque rhadinovirus related to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 encodes a functional homologue of interleukin-6.

Authors:  J A Kaleeba; E P Bergquam; S W Wong
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Antibody-induced and cytoskeleton-mediated redistribution and shedding of viral glycoproteins, expressed on pseudorabies virus-infected cells.

Authors:  H W Favoreel; H J Nauwynck; P Van Oostveldt; T C Mettenleiter; M B Pensaert
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Association of Herpes Viruses with Mild, Moderate and Severe Chronic Periodontitis.

Authors:  Mohammad Mukhit Abdul Gaffar Kazi; Renu Bharadwaj; Kishore Bhat; Daisy Happy
Journal:  J Clin Diagn Res       Date:  2015-07-01

4.  Herpes simplex virus-infected human fibroblasts are resistant to and inhibit cytotoxic T-lymphocyte activity.

Authors:  C M Posavad; K L Rosenthal
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

5.  Low-dose human cytomegalovirus infection of human fibroblast cultures induces lymphokine-activated killer cell resistance: interferon-beta-mediated target cell protection does not correlate with up-regulation of HLA class I surface molecules.

Authors:  K Hamprecht; M Steinmassl
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

6.  Development and antigen specificity of the lymphoproliferation responses of pigs to pseudorabies virus: dichotomy between secondary B- and T-cell responses.

Authors:  T G Kimman; T M De Bruin; J J Voermans; B P Peeters; A T Bianchi
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

7.  Apoptosis mediated by Fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus.

Authors:  M Fleck; E R Kern; T Zhou; J Podlech; W Wintersberger; C K Edwards; J D Mountz
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

8.  HSV-1 antigens and DNA in the corneal explant buttons of patients with non-herpetic or clinically atypical herpetic stromal keratitis.

Authors:  Justus Gerhard Garweg; Christiane Elisabeth Russ; Marc Schellhorn; Matthias Böhnke; Markus Halberstadt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-21       Impact factor: 3.117

9.  Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models.

Authors:  E Manickan; B T Rouse
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Phase-dependent immune evasion of herpesviruses.

Authors:  Tal Vider-Shalit; Vered Fishbain; Shai Raffaeli; Yoram Louzoun
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.